Junyu Chen

TL;DR: Investigation of the therapeutic effect of pioglitazone in the G93A SOD1 transgenic mouse model of ALS suggests that the drug may have therapeutic potential for human ALS.

TL;DR: Deficiency of iNOS substantially protected the AD-like mice from premature mortality, cerebral plaque formation, increased β-amyloid levels, protein tyrosine nitration, astrocytosis, and microgliosis, indicating that inducible nitric oxide synthase may be a therapeutic option in AD.

TL;DR: Celastrol has been widely used in treating inflammatory diseases in man, and is well tolerated; therefore, it may be a promising therapeutic candidate for the treatment of human ALS.

TL;DR: Both thalidomides and lenalidomide bear promise as therapeutic interventions for the treatment of ALS, pharmacological agents that inhibit the expression of TNF-α and other cytokines by destabilizing their mRNA.

TL;DR: The results suggest that agents inhibiting apoptosis and blocking oxidative stress show efficacy in treating mutant-SOD1-associated ALS and that a combination of agents targeting different disease mechanisms may exert additive therapeutic effects.